Chanarin-Dorfman syndrome

Published: 3 June 2021| Version 2 | DOI: 10.17632/x7h75y862m.2
Contributors:
Chloé Valette,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
robert gruber,
,
,
,
,
,
edel o'toole,
,
,

Description

Background: Chanarin-Dorfman syndrome is a rare autosomal recessive disease characterized by accumulation of triglycerides in cells from multiple organs. Its exact prognosis is not well known because of a lack of case series. It is often treated using oral retinoid but risk-benefit ratio of this drug has not been properly studied. Objective: To improve the management of patients by bringing new clinical, molecular and therapeutic data. Methods: Large retrospective multi-center observational research study performed by international expert centers combined with a comprehensive literature search. Results: A total of 38 patients were included. Molecular analysis revealed 19 different mutations including 7 unreported previously. Clinical data and follow-up data were available for 31 patients (median follow-up: 8 years (range: 0 – 38 years)). Skin anomalies (mild to severe ichthyosis) were present in all patients. Liver abnormalities (including 3 cirrhosis) were the most frequent extracutaneous change (28 patients). A total of 17 of the 31 patients received oral retinoids during a median duration of 7.9 years (range: 0.5 – 19.1 years) and one had cirrhosis diagnosed during treatment. Limitations: Retrospective design. Difficulty of comparison with the previously published data because of a lack of standardized reporting outcomes. Conclusion: The risk-benefit ratio appears to be in favor of the use of oral retinoids in cases with severe cutaneous disease.

Files

Institutions

Universite Paul Sabatier Toulouse III Faculte de Medecine Rangueil, Hopital Larrey

Categories

Lipid, Retinoid, Cirrhosis, Ichthyosis

License